I. Meeting Information
The 18th meeting of the 2nd Board of Directors of Hubei Hendi Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") was convened on March 30, 2026, via telephone and email to all directors. A total of 8 directors were required to attend, and all 8 directors participated. The meeting was chaired by the Company's Chairman, Cheng Zhigang, with senior management present. The convening, holding, and voting procedures of this board meeting complied with the relevant provisions of the Company Law of the People's Republic of China and the Company's Articles of Association, making the meeting legal and effective.
II. Meeting Resolutions
The meeting reviewed and approved the following proposals:
-
Approval of the 2025 Board Work Report
The Board of Directors executed the resolutions of the shareholders' meeting in accordance with the Company Law, Articles of Association, and Board Meeting Rules, ensuring standardized, efficient operations and prudent, scientific decision-making to promote the Company's sustainable and stable development. Independent directors Mr. Xiang Guangya, Mr. Yu Junli, and Mr. Yao Ke submitted their annual reports, which will be presented at the 2025 annual shareholders' meeting. The Board prepared a special opinion on the independence of independent directors based on their self-assessment.
Detailed content can be found in the Company's report published on the same day on the Giant Tide Information Network (www.cninfo.com.cn).
Voting results: In favor: 8 votes; Against: 0 votes; Abstained: 0 votes. This proposal was approved and will be submitted for review at the 2025 annual shareholders' meeting. -
Approval of the 2025 Annual Report and Summary
The Company's 2025 Annual Report and Summary comply with legal regulations and accurately reflect the Company's operational situation for the year, with no false records or misleading statements.
Detailed content can be found in the Company's report published on the same day on the Giant Tide Information Network (www.cninfo.com.cn).
Voting results: In favor: 8 votes; Against: 0 votes; Abstained: 0 votes. This proposal was approved and will be submitted for review at the 2025 annual shareholders' meeting.